ProCE Banner Activity

New Data on Monoclonal Antibodies for Prevention and Treatment of COVID-19

Clinical Thought
Neutralizing antibodies are an attractive strategy for prevention and treatment of COVID-19, particularly for unvaccinated persons and others at high risk of infection. Here’s my take on 2 exciting new studies in this field.

Released: July 07, 2021

Expiration: July 06, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Sharon R. Lewin, AO, FRACP, PhD, FAA, FAHMS

Director, Doherty Institute
Melbourne Laureate Professor
Director, Cumming Global Centre for Pandemic Therapeutics
Head, Department of Infectious Diseases
The University of Melbourne
Melbourne, Australia

Sharon Lewin, AO, FRACP, PhD, FAAHMS, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, and ViiV Healthcare; funds for research support from Leidos; and other financial or material support from Gilead Sciences, Merck, and ViiV Healthcare.